Fibroblast growth factor receptors, developmental corruption and malignant disease

Area of Science:

• Molecular Biology
• Genetics
• Developmental Biology

Background:

• Fibroblast growth factors (FGF) are ligands that interact with four cell surface receptors (FGFR1-4).
• FGFRs possess a conserved structure with extracellular Ig-like domains and intracellular tyrosine kinase domains.
• Alternative splicing generates FGFRIIIb and FGFRIIIc isoforms, influencing function and distribution.

Purpose of the Study:

• To review the role of fibroblast growth factor receptor (FGFR) mutations in cancer and developmental syndromes.
• To highlight the shared mutational landscape between oncogenic FGFR alterations and germline mutations causing developmental disorders.
• To discuss the therapeutic potential of targeting the FGF/FGFR signaling pathway.

Main Methods:

• Literature review of studies on FGFR mutations in cancer and developmental syndromes.
• Analysis of shared mutation types and their functional consequences (gain-of-function, gene amplification).
• Comparison of ontologic features associated with specific FGFR mutations.

Main Results:

• Somatic FGFR mutations are prevalent in various cancers, often exhibiting gain-of-function activity or gene amplification (e.g., FGFR1 in lung cancer).
• Germline FGFR mutations are associated with developmental syndromes, notably craniosynostosis (e.g., FGFR2 in Apert syndrome).
• Identical mutations can be found in both cancer and developmental disorders, indicating conserved pathogenic mechanisms.

Conclusions:

• FGFR mutations play a critical role in both oncogenesis and embryonic development.
• The study of FGFR mutations provides insights into shared molecular pathways across diseases.
• Targeted therapies inhibiting FGF/FGFR signaling represent a promising avenue for clinical intervention in FGFR-driven cancers.